The deal with the Korean government covers the manufacturing and commercialization of NVX-CoV2373, expanding on a prior technology transfer agreement. Doses will be available to citizens in the Republic of Korea this year, the companies said in a statement.

Novovax's NVX-CoV2373 is a protein-based vaccine candidate developed with the company's proprietary recombinant nanoparticle technology. The liquid product is stable with refrigeration, which the company says eases distribution.

Novavax begins several rolling regulatory reviews for its COVID-19 vaccine
Novavax has started the rolling review process for authorization of its COVID-19 vaccine, NVX-CoV2373, by multiple regulatory agencies.

Novavax to supply Switzerland with 6M doses of COVID-19 vaccine
Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving...

Canada ups COVID-19 vaccine order from Novavax to 76M doses
Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19...

Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward...